These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

784 related articles for article (PubMed ID: 32900861)

  • 1. TIGIT in cancer immunotherapy.
    Chauvin JM; Zarour HM
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
    Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
    Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene of the month: T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT).
    Bolm L; Petruch N; Sivakumar S; Annels NE; Frampton AE
    J Clin Pathol; 2022 Apr; 75(4):217-221. PubMed ID: 35058314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TIGIT: An emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer.
    Zhao J; Li L; Yin H; Feng X; Lu Q
    Int Immunopharmacol; 2023 Jul; 120():110358. PubMed ID: 37262959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting novel inhibitory receptors in cancer immunotherapy.
    Ding QQ; Chauvin JM; Zarour HM
    Semin Immunol; 2020 Jun; 49():101436. PubMed ID: 33288379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.
    Hansen K; Kumar S; Logronio K; Whelan S; Qurashi S; Cheng HY; Drake A; Tang M; Wall P; Bernados D; Leung L; Ophir E; Alteber Z; Cojocaru G; Galperin M; Frenkel M; White M; Hunter J; Liang SC; Kotturi MF
    Cancer Immunol Immunother; 2021 Dec; 70(12):3525-3540. PubMed ID: 33903974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy.
    Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Zhao X; Yu Y; Zhang H; Xu F; Tian Y
    J Exp Clin Cancer Res; 2021 Aug; 40(1):267. PubMed ID: 34433460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8
    Banta KL; Xu X; Chitre AS; Au-Yeung A; Takahashi C; O'Gorman WE; Wu TD; Mittman S; Cubas R; Comps-Agrar L; Fulzele A; Bennett EJ; Grogan JL; Hui E; Chiang EY; Mellman I
    Immunity; 2022 Mar; 55(3):512-526.e9. PubMed ID: 35263569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
    Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy.
    Mu Y; Guan X
    Curr Med Chem; 2024; 31(13):1634-1645. PubMed ID: 38666504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
    Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J
    Front Immunol; 2021; 12():699895. PubMed ID: 34367161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy.
    Liu XG; Hou M; Liu Y
    Immunol Invest; 2017 Feb; 46(2):172-182. PubMed ID: 27819527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways.
    Yang J; Wang L; Byrnes JR; Kirkemo LL; Driks H; Belair CD; Aguilar OA; Lanier LL; Wells JA; Fong L; Blelloch R
    Cancer Immunol Res; 2024 May; 12(5):575-591. PubMed ID: 38588410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.
    Boissière-Michot F; Chateau MC; Thézenas S; Guiu S; Bobrie A; Jacot W
    Front Immunol; 2022; 13():1058424. PubMed ID: 36544779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy.
    Wang D; Gu Y; Yan X; Huo C; Wang G; Zhao Y; Teng M; Li Y
    Front Oncol; 2022; 12():844260. PubMed ID: 35433470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIGIT: a novel immunotherapy target moving from bench to bedside.
    Solomon BL; Garrido-Laguna I
    Cancer Immunol Immunother; 2018 Nov; 67(11):1659-1667. PubMed ID: 30232519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
    Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
    Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 40.